| Q38269499 | Enzymatic aspects in ENT cancer-Matrix metalloproteinases. |
| Q47753186 | Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients |
| Q43746137 | Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. |
| Q24568374 | Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression |
| Q33692934 | MMP inhibition in prostate cancer |
| Q35083825 | Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue |
| Q42053210 | Matrix metalloproteinases (MMPs) in fresh human prostate tumour tissue and organ-cultured prostate tissue: levels of collagenolytic and gelatinolytic MMPs are low, variable and different in fresh tissue versus organ-cultured tissue |
| Q34254356 | Matrix metalloproteinases and angiogenic factors: predictors of survival after radical prostatectomy for clinically organ-confined prostate cancer? |
| Q33692926 | Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications |
| Q40984822 | Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells |
| Q35763791 | Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma |
| Q39139686 | Skip Regulates TGF- β 1-Induced Extracellular Matrix Degrading Proteases Expression in Human PC-3 Prostate Cancer Cells. |
| Q37224569 | Transglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-κB Pathway |